Seminars in Hematology
Volume 40, Issue 1 , Pages 34-49 , January 2003

Management of chronic myeloid leukemia: Targets for molecular therapy

References 

  1. Adjei AA, Erlichman C, Davis JN, et al.  A phase I trial of the farnesyl transferase inhibitor SCH66336: Evidence for biological and clinical activity. Cancer Res. 2000;60:1871–1877
  2. Akiyama T, Ishida J, Nakagawa S, et al.  Genistein, a specific inhibitor of tyrosine-specific protein kinases. J Biol Chem. 1987;262:5592–5595
  3. Amrolia PJ, Reid SD, Gao L, et al: Allo-restricted cytotoxic T-cells specific for human CD45 show potent anti-leukemic activity. Blood (in press)
  4. An WG, Schulte TW, Neckers LM. The heat shock protein 90 antagonist geldanamycin alters chaperone association with p210bcr-abl and v-src proteins before their degradation by the proteasome. Cell Growth Differ. 2000;11:355–360
  5. Anafi M, Gazit A, Zehavi A, et al.  Tyrphostin-induced inhibition of p210bcr-abl tyrosine kinase activity induces K562 to differentiate. Blood. 1993;82:3524–3529
  6. Barthe C, Cony-Makhoul P, Melo JV, et al.  Roots of clinical resistance to STI-571 cancer therapy. Science. 2001;293:2163; (letter)
  7. Berezov A, Chen J, Liu Q, et al.  Disabling receptor ensembles with rationally designed interface peptidomimetics. J Biol Chem. 2002;277:28330–28339
  8. Blagosklonny MV. Hsp-90-associated oncoproteins: Multiple targets of geldanamycin and its analogs. Leukemia. 2002;16:455–462
  9. Blagosklonny MV. STI-571 must select for drug-resistant cells but ‘no cell breathes fire out of its nostrils like a dragon’. Leukemia. 2002;16:570–572
  10. Braasch DA, Corey DR. Novel antisense and peptide nucleic acid strategies for controlling gene expression. Biochemistry. 2002;41:4503–4510
  11. Branford S, Rudzki Z, Walsh S, et al.  High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance. Blood. 2002;99:3472–3475
  12. Buchdunger E, Cioffi CL, Law N, et al.  Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. J Pharmacol Exp Ther. 2000;295:139–145
  13. Buchdunger E, Zimmermann J, Mett H, et al.  Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative. Cancer Res. 1996;56:100–104
  14. Capdeville R, Buchdunger E, Zimmermann J, et al.  Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug. Nat Rev Drug Discov. 2002;1:493–502
  15. Cobaleda C, Sànchez-Garcia I. In vivo inhibition by a site-specific catalytic RNA subunit of RNase P designed against the BCR-ABL oncogenic products: A novel approach for cancer treatment. Blood. 2000;95:731–737
  16. de Fabritiis P, Petti MC, Montefusco E, et al.  BCR-ABL antisense oligodeoxynucleotide in vitro purging and autologous bone marrow transplantation for patients with chronic myelogenous leukemia in advanced phase. Blood. 1998;91:3156–3162
  17. Deininger MW, Goldman JM, Lydon N, et al.  The tyrosine kinase inhibitor CGP57148B selectively inhibits the growth of BCR-ABL-positive cells. Blood. 1997;90:3691–3698
  18. Dhut S, Chaplin T, Young BD:. BCR-ABL and BCR proteins: Biochemical characterization and localization. Leukemia. 1990;4:745–750
  19. Dorsey JF, Jove R, Kraker AJ, et al.  The pyrido[2,3-d]pyrimidine derivative PD180970 inhibits p210Bcr-Abl tyrosine kinase and induces apoptosis of K562 leukemic cells. Cancer Res. 2000;60:3127–3131
  20. Druker BJ, Lydon NB. Lessons learned from the development of an abl tyrosine kinase inhibitor for chronic myelogenous leukemia. J Clin Invest. 2000;105:3–7
  21. Druker BJ, Talpaz M, Resta DJ, et al.  Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med. 2001;344:1031–1037
  22. Druker BJ, Tamura S, Buchdunger E, et al.  Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med. 1996;2:561–566
  23. Gao L, Bellantuono I, Elsasser A, et al.  Selective elimination of leukemic CD34(+) progenitor cells by cytotoxic T lymphocytes specific for WT1. Blood. 2000;95:2198–2203
  24. Gibbs JB, Oliff A, Kohl NE. Farnesyltransferase inhibitors: Ras research yields a potential cancer therapeutic. Cell. 1994;77:175–178
  25. Gorre ME, Ellwood-Yen K, Chiosis G, et al.  BCR-ABL point mutants isolated from patients with imatinib mesylate-resistant chronic myeloid leukemia remain sensitive to inhibitors of the BCR-ABL chaperone heat shock protein 90. Blood. 2002;100:3041–3044
  26. Gorre ME, Mohammed M, Ellwood K, et al.  Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science. 2001;293:876–880
  27. Guo XY, Cuillerot JM, Wang T, et al.  Peptide containing the BCR oligomerization domain (AA 1-160) reverses the transformed phenotype of p210bcr-abl positive 32D myeloid leukemia cells. Oncogene. 1998;17:825–833
  28. He Y, Wertheim JA, Xu L, et al.  The coiled-coil domain and Tyr177 of bcr are required to induce a murine chronic myelogenous leukemia-like disease by bcr/abl. Blood. 2002;99:2957–2968
  29. Hofmann WK, Jones LC, Lemp NA, et al.  Ph(+) acute lymphoblastic leukemia resistant to the tyrosine kinase inhibitor STI571 has a unique BCR-ABL gene mutation. Blood. 2002;99:1860–1862
  30. Honma Y, Okabe-Kado J, Hozumi M, et al.  Induction of erythroid differentiation of K562 human leukemic cells by herbimycin A, an inhibitor of tyrosine kinase activity. Cancer Res. 1989;49:331–334
  31. Hoover RR, Mahon FX, Melo JV, et al.  Overcoming STI571 resistance with the farnesyl transferase inhibitor SCH66336. Blood. 2002;100:1068–1071
  32. Ilaria RL, Van Etten RA. P210 and P190(BCR/ABL) induce the tyrosine phosphorylation and DNA binding activity of multiple specific STAT family members. J Biol Chem. 1996;71:31704–31710
  33. James HA, Gibson I. The therapeutic potential of ribozymes. Blood. 1998;91:371–382
  34. Kang CD, Yoo SD, Hwang BW, et al.  The inhibition of ERK/MAPK not the activation of JNK/SAPK is primarily required to induce apoptosis in chronic myelogenous leukemic K562 cells. Leuk Res. 2000;24:527–534
  35. Kano Y, Akutsu M, Tsunoda S, et al.  In vitro cytotoxic effects of a tyrosine kinase inhibitor STI571 in combination with commonly used antileukemic agents. Blood. 2001;97:1999–2007
  36. Kantarjian H, Sawyers C, Hochhaus A, et al.  Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med. 2002;346:645–652
  37. Kardinal C, Konkol B, Lin H, et al.  Chronic myelogenous leukemia blast cell proliferation is inhibited by peptides that disrupt Grb2-SoS complexes. Blood. 2001;98:1773–1781
  38. Kardinal C, Konkol B, Schulz A, et al.  Cell-penetrating SH3 domain blocker peptides inhibit proliferation of primary blast cells from CML patients. FASEB J. 2000;14:1529–1538
  39. Karp JE, Lancet JE, Kaufmann SH, et al.  Clinical and biologic activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: A phase 1 clinical-laboratory correlative trial. Blood. 2001;97:3361–3369
  40. Kato K, Cox AD, Hisaka MM, et al.  Isoprenoid addition to Ras protein is the critical modification for its membrane association and transforming activity. Proc Natl Acad Sci USA. 1992;89:6403–6407
  41. Klejman A, Rushen L, Morrione A, et al.  Phosphatidylinositol-3 kinase inhibitors enhance the anti-leukemia effect of STI571. Oncogene. 2002;21:5868–5876
  42. La Rosée P, Johnson K, O'Dwyer ME, et al.  In vitro studies of the combination of imatinib mesylate (Gleevec) and arsenic trioxide (Trisenox) in chronic myelogenous leukemia. Exp Hematol. 2002;30:729–737
  43. Lebowitz PF, Du W, Prendergast GC. Prenylation of RhoB is required for its cell transforming function but not its ability to activate serum response element-dependent transcription. J Biol Chem. 1997;272:16093–16095
  44. Levitzki A, Gazit A. Tyrosine kinase inhibition: An approach to drug development. Science. 1995;267:1782–1788
  45. Luger SM, O'Brien SG, Ratajczak J, et al.  Oligodeoxynucleotide-mediated inhibition of c-myb gene expression in autografted bone marrow: A pilot study. Blood. 2002;99:1150–1158
  46. Lugo TG, Pendergast AM, Muller AJ, et al.  Tyrosine kinase activity and transformation potency of bcr-abl oncogene products. Science. 1990;247:1079–1082
  47. Luzzatto L, Melo JV. Acquired resistance to imatinib mesylate: Selection for pre-existing mutant cells. Blood. 2002;100:1105; (letter)
  48. Mahon FX, Deininger MW, Schultheis B, et al.  Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: Diverse mechanisms of resistance. Blood. 2000;96:1070–1079
  49. Marais R, Light Y, Paterson HF, et al.  Ras recruits Raf-1 to the plasma membrane for activation by tyrosine phosphorylation. EMBO J. 1995;14:3136–3145
  50. Marley SB, Davidson RJ, Goldman JM, et al.  Effects of combinations of therapeutic agents on the proliferation of progenitor cells in chronic myeloid leukaemia. Br J Haematol. 2002;116:162–165
  51. McWhirter JR, Galasso DL, Wang JY. A coiled-coil oligomerization domain of Bcr is essential for the transforming function of Bcr-Abl oncoproteins. Mol Cell Biol. 1993;13:7587–7595
  52. Melo JV. The diversity of BCR-ABL fusion proteins and their relationship to leukemia phenotype. Blood. 1996;88:2375–2384
  53. Melo JV. Inviting leukaemic cells to waltz with the devil. Nat Med. 2001;7:156–157
  54. Morgan MA, Dolp O, Reuter CW. Cell-cycle-dependent activation of mitogen-activated protein kinase kinase (MEK-1/2) in myeloid leukemia cell lines and induction of growth inhibition and apoptosis by inhibitors of RAS signaling. Blood. 2001;97:1823–1834
  55. Mow BM, Chandra J, Svingen PA, et al.  Effects of the Bcr/abl kinase inhibitors STI571 and adaphostin (NSC 680410) on chronic myelogenous leukemia cells in vitro. Blood. 2002;99:664–671
  56. Nimmanapalli R, O'Bryan E, Bhalla K. Geldanamycin and its analogue 17-allylamino-17-demethoxygeldanamycin lowers Bcr-Abl levels and induces apoptosis and differentiation of Bcr-Abl-positive human leukemic blasts. Cancer Res. 2001;61:1799–1804
  57. Nowell PC, Hungerford DA. A minute chromosome in human chronic granulocytic leukemia. Science. 1960;132:1497
  58. O'Dwyer M. Multifaceted approach to the treatment of bcr-abl-positive leukemias. Oncologist. 2002;7(suppl 1):30–38
  59. Oda T, Heaney C, Hagopian JR, et al.  Crkl is the major tyrosine-phosphorylated protein in neutrophils from patients with chronic myelogenous leukemia. J Biol Chem. 1994;269:22925–22928
  60. Okuda K, Weisberg E, Gilliland DG, et al.  ARG tyrosine kinase activity is inhibited by STI571. Blood. 2001;97:2440–2448
  61. Pelicci G, Lanfrancone L, Salcini AE, et al.  Constitutive phosphorylation of Shc proteins in human tumors. Oncogene. 1995;11:899–907
  62. Pendergast AM, Quilliam LA, Cripe LD, et al.  BCR-ABL-induced oncogenesis is mediated by direct interaction with the SH2 domain of the GRB-2 adaptor protein. Cell. 1993;75:175–185
  63. Peters DG, Hoover RR, Gerlach MJ, et al.  Activity of the farnesyl protein transferase inhibitor SCH66336 against BCR/ABL-induced murine leukemia and primary cells from patients with chronic myeloid leukemia. Blood. 2001;97:1404–1412
  64. Pinilla-Ibarz J, Cathcart K, Korontsvit T, et al.  Vaccination of patients with chronic myelogenous leukemia with bcr-abl oncogene breakpoint fusion peptides generates specific immune responses. Blood. 2000;95:1781–1787
  65. Puil L, Liu J, Gish G, et al.  Bcr-Abl oncoproteins bind directly to activators of the Ras signalling pathway. EMBO J. 1994;13:764–773
  66. Reichert A, Heisterkamp N, Daley GQ, et al.  Treatment of Bcr/Abl-positive acute lymphoblastic leukemia in P190 transgenic mice with the farnesyl transferase inhibitor SCH66336. Blood. 2001;97:1399–1403
  67. Sawyers CL, Hochhaus A, Feldman E, et al.  Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: Results of a phase II study. Blood. 2002;99:3530–3539
  68. Schultheis B, Yong ASM, Goldman JM, et al.  The combined use of STI571 and leptomycin-B (LMB) for in vitro purging of leukemic cells in autografts for CML. Blood. 2001;98(suppl 1, abstr):618a
  69. Shah NP, Nicoll JM, Nagar B, et al.  Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell. 2002;2:117–125
  70. Skorski T, Kanakaraj P, Nieborowska-Skorska M, et al.  Phosphatidylinositol-3 kinase activity is regulated by BCR/ABL and is required for the growth of Philadelphia chromosome-positive cells. Blood. 1995;86:726–736
  71. Skorski T, Nieborowska-Skorska M, Nicolaides NC, et al.  Suppression of Philadelphia1 leukemia cell growth in mice by BCR-ABL antisense oligodeoxynucleotide. Proc Natl Acad Sci USA. 1994;91:4504–4508
  72. Spiller DG, Giles RV, Grzybowski J, et al.  Improving the intracellular delivery and molecular efficacy of antisense oligonucleotides in chronic myeloid leukemia cells: A comparison of streptolysin-O permeabilization, electroporation, and lipophilic conjugation. Blood. 1998;91:4738–4746
  73. Taagepera S, McDonald D, Loeb JE, et al.  Nuclear-cytoplasmic shuttling of C-ABL tyrosine kinase. Proc Natl Acad Sci USA. 1998;95:7457–7462
  74. Talpaz M, Silver RT, Druker BJ, et al.  Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: Results of a phase 2 study. Blood. 2002;99:1928–1937
  75. Tanabe T, Kuwabara T, Warashina M, et al.  Oncogene inactivation in a mouse model. Nature. 2000;406:473–474
  76. Thiesing JT, Ohno-Jones S, Kolibaba KS, et al.  Efficacy of STI571, an abl tyrosine kinase inhibitor, in conjunction with other antileukemic agents against bcr-abl-positive cells. Blood. 2000;96:3195–3199
  77. Tipping AJ, Mahon FX, Zafirides G, et al: Drug responses of STI571-resistant cells: synergism of STI571 with other chemotherapeutic drugs. Leukemia (in press)
  78. Topaly J, Zeller WJ, Fruehauf S. Synergistic activity of the new ABL-specific tyrosine kinase inhibitor STI571 and chemotherapeutic drugs on BCR-ABL-positive chronic myelogenous leukemia cells. Leukemia. 2001;15:342–347
  79. Uehara Y, Hori M, Takeuchi T, et al.  Phenotypic change from transformed to normal induced by benzoquinonoid ansamycins accompanies inactivation of p60src in rat kidney cells infected with Rous sarcoma virus. Mol Cell Biol. 1986;6:2198–2206
  80. Van Etten RA. Cycling, stressed-out and nervous: cellular functions of c-Abl. Trends Cell Biol. 1999;9:179–186
  81. Vigneri P, Wang JY. Induction of apoptosis in chronic myelogenous leukemia cells through nuclear entrapment of BCR-ABL tyrosine kinase. Nat Med. 2001;7:228–234
  82. von Bubnoff N, Schneller F, Peschel C, et al.  BCR-ABL gene mutations in relation to clinical resistance of Philadelphia-chromosome-positive leukaemia to STI571: A prospective study. Lancet. 2002;359:487–491
  83. Voncken JW, van Schaick H, Kaartinen V, et al.  Increased neutrophil respiratory burst in bcr-null mutants. Cell. 1995;80:719–728
  84. Walker EH, Pacold ME, Perisic O, et al.  Structural determinants of phosphoinositide 3-kinase inhibition by wortmannin, LY294002, quercetin, myricetin, and staurosporine. Mol Cell. 2000;6:909–919
  85. Wen ST, Jackson PK, Van Etten RA. The cytostatic function of c-Abl is controlled by multiple nuclear localization signals and requires the p53 and Rb tumor suppressor gene products. EMBO J. 1996;15:1583–1595
  86. Whitesell L, Mimnaugh EG, De Costa B, et al.  Inhibition of heat shock protein HSP90-pp60v-src heteroprotein complex formation by benzoquinone ansamycins: Essential role for stress proteins in oncogenic transformation. Proc Natl Acad Sci USA. 1994;91:8324–8328
  87. Wisniewski D, Lambek CL, Liu C, et al.  Characterization of potent inhibitors of the Bcr-Abl and the c-kit receptor tyrosine kinases. Cancer Res. 2002;62:4244–4255
  88. Wu Y, Yu L, McMahon R, et al.  Inhibition of bcr-abl oncogene expression by novel deoxyribozymes (DNAzymes). Hum Gene Ther. 1999;10:2847–2857
  89. Yaish P, Gazit A, Gilon C, et al.  Blocking of EGF-dependent cell proliferation by EGF receptor kinase inhibitors. Science. 1988;242:933–935
  90. Yu C, Krystal G, Varticovksi L, et al.  Pharmacologic mitogen-activated protein/extracellular signal-regulated kinase kinase/mitogen-activated protein kinase inhibitors interact synergistically with STI571 to induce apoptosis in Bcr/Abl-expressing human leukemia cells. Cancer Res. 2002;62:188–199
  91. Zhao X, Ghaffari S, Lodish H, et al.  Structure of the Bcr-Abl oncoprotein oligomerization domain. Nat Struct Biol. 2002;9:117–120

☆ Address reprint requests to Professor Junia V. Melo, Department of Haematology-ICSTM, Hammersmith Hospital, Du Cane Road, London W12 0NN, UK.

PII: S0037-1963(03)70041-9

Seminars in Hematology
Volume 40, Issue 1 , Pages 34-49 , January 2003

Article Tools

* Image Usage & Resolution